Patent details
300837 Product Name: Elotuzumab, lenalidomide en dexamethason
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
- Publication number:
- 300837
- Type:
- Certificate
- SPC Type:
- Medical
- Basic Patent Number:
- EP2068874
- Status:
- Withdrawn
- Application number:
- 300837
- Procedural language:
- Dutch
- First Applicant Residence Country:
- United States of America (US)
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1088
- Marketing Authorization Type:
- EEA
- Marketing Authorization Date:
- 13/05/2016
- Marketing Authorization Country:
- European Union (EU)
Dates
- Filing date:
- 25/10/2016
- First Marketing Authorization date:
- 13/05/2016
- Grant date:
- Activation date:
- Lapsed By Non Payment Annual Fee Date:
- Renunciation Date:
- NullificationDate:
- Registration date:
- 26/10/2016
- SPC/SPC Extension Expiration Date:
- 12/05/2031
- Lapsed By Expiration Date:
- Withdrawal date:
- 21/12/2016
- Revocation Date:
- Invalidity Date:
- Withdrawal Market Authorization Date:
- Refusal Date:
Applicant/holder
- From:
- 26/10/2016
- Name:
- AbbVie Biotherapeutics Inc.
- Address:
- 1500 Seaport Boulevard, REDWOOD CITY, CA 94063, United States of America (US)
- From:
- 26/10/2016
- Name:
- Dana-Farber Cancer Institute, Inc.
- Address:
- 450 Brookline Avenue, BOSTON, MA 02215-5450, United States of America (US)
Agent
- Name:
- ir. F.A. Geurts c.s.
- From:
- 26/10/2016
- Address:
- Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- VRV
- Journal edition number:
- 01/17
- Publication date:
- 04/01/2017
- Description:
- Lapse or annulment
2
- Bulletin Heading:
- SPC
- Journal edition number:
- 43/16
- Publication date:
- 28/10/2016
- Description:
- Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
| Filing date | Document type | Document Description | Number of pages | File Type | ||
|---|---|---|---|---|---|---|
| 21/12/2016 | Incoming Correspondence Paper | Response applicant or agent | 1 | /9/9/3/1/0/0800101399/docs/300837_10_incomingcorrespondencepaper20161222020806728.pdf | ||
| 17/11/2016 | Outgoing Correspondence | Letter to applicant | 3 | /9/9/3/1/0/0800101399/docs/300837_1_96935l173.pdf | ||
| 17/11/2016 | Outgoing Correspondence | Outgoing Letter | 3 | /9/9/3/1/0/0800101399/docs/300837_6_outgoingcorrespondence20161118093729820.pdf | ||
| 28/10/2016 | Outgoing Correspondence | Confirmation receipt request | 1 | /9/9/3/1/0/0800101399/docs/300837_4_94030l174.pdf | ||
| 25/10/2016 | SPC Documents | Marketing Authorization SPC | 3 | /9/9/3/1/0/0800101399/docs/300837_0_supplprotectioncertificate20161026041625373.pdf | ||
| 25/10/2016 | SPC Documents | Annex SPC | 3 | /9/9/3/1/0/0800101399/docs/300837_2_supplprotectioncertificate20161026041625129.pdf | ||
| 25/10/2016 | Application Form | First filed application form | 3 | /9/9/3/1/0/0800101399/docs/300837_3_applicationform20161026041624892.pdf | ||
| 25/10/2016 | SPC Documents | Annex SPC | 1 | /9/9/3/1/0/0800101399/docs/300837_5_supplprotectioncertificate20161026041625223.pdf | ||
| 25/10/2016 | SPC Documents | Summary of the characteristics of the product | 19 | /9/9/3/1/0/0800101399/docs/300837_7_supplprotectioncertificate20161026041625448.pdf | ||
| 25/10/2016 | Incoming Correspondence Paper | Response applicant or agent | 3 | /9/9/3/1/0/0800101399/docs/300837_8_incomingcorrespondencepaper20161026041625045.pdf | ||
| 25/10/2016 | SPC Documents | Marketing Authorization SPC | 1 | /9/9/3/1/0/0800101399/docs/300837_9_supplprotectioncertificate20161026041625540.pdf | ||
| 25/10/2016 | SPC Documents | Annex SPC | 2 | /9/9/3/1/0/0800101399/docs/300837_11_supplprotectioncertificate20161026041625298.pdf |